Extemporaneous orphan drugs and preparations for rare diseases: Organisation and management of an inter-regional network

EJHP Practice

Volumn 17, Issue 3, 2011, Pages 40-46

  Peila, E ^a   Fogliano, M R ^a   Crosasso, P ^b   Mosso, B ^b   Chiappetta, M R ^b   Viterbo, M L ^b   Mazengo, M ^c   Stecca, S ^b   Baldovino, S ^a   Roccatello, D ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Unit of Pneumology   (Italy)

Author keywords

Extemporaneous compounding preparation; Hospital pharmacist; Rare diseases; Ubidecarenone

Indexed keywords

ALFACALCIDOL; ANTIOXIDANT; CALCITRIOL; CLOBETASOL; COCOA FLAVOURED PHOSPHATE SOLUTION; EDETIC ACID; EYE DROPS; GLUTATHIONE; ORPHAN DRUG; RIBOFLAVIN; UBIDECARENONE; UNCLASSIFIED DRUG;

ACQUIRED OPTIC NEUROPATHY; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BONE MALFORMATION; BRAIN DISEASE; CALCIFIC BAND KERATOPATHY; COQ10 DEFICIENCY SYNDROME; DEGENERATIVE DISEASE; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DRUG TOLERABILITY; ELECTRON TRANSPORT; ENZYME DEFICIENCY; HOSPITAL PHARMACY; HUMAN; HUNTINGTON CHOREA; INTERREGIONAL NETWORK; KERATOPATHY; LACTIC ACIDOSIS; MELAS SYNDROME; MITOCHONDRIAL MYOPATHY; OPTIC NERVE DISEASE; ORAL PEMPHIGO; ORGANIZATION; ORGANIZATION AND MANAGEMENT; OXIDATIVE STRESS; PEMPHIGOID; PRESCRIPTION; QUALITY CONTROL; RARE DISEASE; REGISTER; RICKETS; STANDARDIZATION; TREATMENT PLANNING; VITAMIN D RESISTANT HYPOPHOSPHATEMIC RICKETS;

EID: 80053906626     PISSN: 17819989     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (33)

1. D.M. May, 18th 2001, n. 279. Regolamento di istituzione della rete nazionale delle malattie rare e di esenzione dalla partecipazione al costo delle relative prestazioni sanitarie, ai sensi dell'articolo 5, comma 1, lettera b), del decreto legislativo 29 aprile 1998, n. 124. (GU n. 160 del 12-7-2001-Suppl. Ordinario n.180/L).
2. Delibera della Giunta Regionale. March 2nd, 2004, n.22-11870, B. U. n.13 del 1/04/2004.
3. Delibera della Giunta Regionale. February 1 st, 2008, n. 234.
4. Law, December 24th 2007, n.244-Finanziaria 2008, Disposizioni per la formazione del bilancio annuale e pluriennale dello Stato.
5. www.ministerosalute.it/imgs/C_17_normativa_194_ulterioriallegati_ ulterioreallegato0_alleg.xls Rare Diseases' codes website
6. www.malattierarepiemonte.it/documents/elencoregionalemalattierare. pdf Rare Diseases list in Piedmont and Aosta Valley.
7. Italian Pharmacopoeia XII edition: Good preparation rules for extemporaneous compounding (NBP).
8. Young AJ, Johnson S, Steffens DC, Doraiswamy PM. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 2007;12(1):62-8.
9. Rodriguez MC. Beneficial effects of creatine, CoQ10 and lipoic acid in mitochondrial disorders. Muscle Nerve. 2007;35(2):2350-42.
10. Panetta J. Effect of high-dose vitamins, coenzyme Q and high-fat diet in paediatric patients with mitochondrial diseases. J Inherit Metab Dis. 2004;27(4):487-98.
11. Chen RS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol. 1997;37(4):212-8.
12. Chan A. Metabolic changes in patients with mitochondrial myopathies and effects of Coenzyme Q10 therapy. J Neurol. 1998;245(10):681-5.
13. Montero R, Artuch R, Briones P, Nascimento A, et al. Muscle coenzyme Q10 concentrations in patients with probable and definite diagnosis of respiratory chain disorders. Biofactors. 2005;25(1-4):109-15.
14. Artuch R, Brea-Calvo G, Briones P, Aracil A, et al. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci. 2006;246(1-2):153-8.
15. Zhipeng W. Toxicity of Coenzyme Q10: a report of 90-day repeated dose toxicity study in rats. J Toxicol Sci. 2007:32(5):505-14.
16. Bouillon R, et al. Intestinal calcium absorption: molecular vitamin D mediated mechanism. J Cell Bioch. 2003;88(2):332-9.
17. Rowe PS. The molecular background to hypophosphatemic rickets. Arch Dis Child. 2000; 83(13):192-4.
18. Kasper H, Braunwald E, Hauser S, Longo D, Jameson L, Fauci AS. Harrison's Principles of Internal Medicine. 16th ed, volume II, McGraw-Hill Professional; 2004. p.1917.
19. Baroncelli G, et al. Effect of GH treatment on final height, phosphate metabolism, and BMD in children with X-linked hypophosphatemic rickets. J Pediatr. 2001;138:236-43.
20. Joly P, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(7):1681-7.
21. Joly P, Fontaine J, Roujeau JC. The role of topical corticosteroids in bullous pemphigoid in the elderly. Drugs Aging. 2005;22(7): 571-6.
22. Najjar DM, et al. EDTA chelation for calcific band keratopathy: results and long-term follow-up. Am J Ophthalmol. 2004;137(6):1056-64.
23. Bouillon R, et al. Intestinal calcium absorption: molecular vitamin D mediated mechanism. J Cell Biochem. 2003;88(2):332-9.
24. Rowe PS, et al. The molecular background to hypophosphatemic rickets. Arch Dis Child. 2000;83(3):192-4.
25. Baroncelli GI, et al. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr. 2001;138(2):236-43.
26. Harrison. Principi di Medicina Interna.16th ed. New York McGraw Hill; 2007. p.1917.
27. Carelli V, Ross-Cisneros FN, Sadun AA. Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem Int. 2002;40(6):573-84.
28. Toscano A. Coenzima Q e malattie mitocondriali: dalla biochimica alle implicazioni terapeutiche. Musumeci O Neurol Sci. 2004:2S: S317-319.
29. Montero R, Artuch R, Briones P, Nascimento A, et al. Muscle coenzyme Q10 concentrations in patients with probable and definite diagnosis of respiratory chain disorders. Biofactors. 2005;25(1-4):109-15.
30. Artuch R, Brea-Calvo G, Briones P, Aracil A, et al. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci. 2006;246(1-2):153-8.
31. Ferrante KL, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005;65(11):1834-6.
32. Young AJ, Johnson S, Steffens DC, Doraiswamy PM. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 2007;12(1): 62-8.
33. Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors. 1999;9(2-4):261-6.